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Abstract Electrical activity of myotubes represses nicotinic
acetylcholine receptor (AChR) gene expression. This effect is
mimicked by okadaic acid and blocked by tetrodotoxin (TTX) or
staurosporine in cultured myocytes [Altiok et al., EMBO J. 16
(1997) 717^725]. In this study, we investigated the mechanism of
this repression. We show that addition of exogenous phospho-
lipase D (PLD) and C inhibits AChR expression in a manner
which parallels that of okadaic acid. Furthermore, okadaic acid
caused an increase of the threonine phosphorylation of protein
kinase Cj (PKCj) and activator of transcription factor (ATF2)
and a decrease of the phosphorylation of Sp1. All these effects
were reversed by staurosporine, and TTX also abolished ATF2
phosphorylation. These data reveal a possible involvement of
PLD, c-jun N-terminal kinase, PKCj and Sp1 in the repression
of AChR genes by electrical activity. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Neurally elicited electrical activity represses nicotinic acetyl-
choline receptor (AChR) gene expression in the extrajunction-
al areas of skeletal muscle ¢bers during development, and in
the adult [1]. In vitro, the spontaneous, or neurally elicited,
electrical activity of cultured myotubes represses AChR syn-
thesis, whereas treatment of myotubes with the Na channel
blocker tetrodotoxin (TTX), or with Ca2 channel blockers,
increases AChR K-subunit mRNA levels by preventing Ca2
entry via L-type channels [2^4]. Earlier studies using phorbol
esters have suggested the implication of a Ca2 activated con-
ventional protein kinase C (PKC), but a direct demonstration
of its involvement has not been provided [5,6]. The studies
mentioned so far have focused on conventional PKCs, where-
as other Ca2 activated pathways have not been considered.
To address this question we have investigated the possible
contribution of a serine/threonine kinase (Ser/Thr kinase)
and of its activation pathway by Ca2 in£ux in electrically
active myotubes. Here, we provide evidence in favor of the
activation of c-jun N-terminal kinase (JNK) and PKCj to-
gether with the dephosphorylation of Sp1 ^ at least partially
via the stimulation of phospholipase D (PLD) ^ in the trans-
duction pathway mediating repression of AChR genes by elec-
trical activity.
2. Materials and methods
2.1. Materials
[Q-33P]ATP, [32P]UTP and [methyl-3H]choline chloride were from
Amersham Corp. GF109203X was kindly provided by Dr. Jorge Kiri-
lovsky (Lab. Glaxo, France). HA1004 was from Biomol Research
Lab, USA. Staurosporine was from Research Biochemicals, USA.
Okadaic acid was from Upstate Biotechnology Inc. Anti-PKCj anti-
body was from Santa Cruz Biotechnology Inc., anti-phosphothreo-
nine, anti-phospho-activator or transcription factor (ATF2) and
anti-ATF2 were from New England Biolabs. All other reagents in-
cluding phospholipase D (Streptomyces chromofuscus, type VII) and
phospholipase C (PLC, Bacillus cereus, type V), were from Sigma
Chemical Co.
2.2. Primary culture of chick myotubes
Myoblasts were obtained from the hindlimbs of 11 day old chick
embryos by mechanical dissociation and seeded at a density of 2U104
cells/mm2 in gelatin coated, plastic dishes and grown in medium con-
taining 4% horse serum and 2% embryonic extract, as described pre-
viously [2].
2.3. PKC activity assay
PKC activity was determined using a PKC assay kit (Upstate Bio-
technology). Synthetic peptides corresponding to amino acids 4^14 of
myelin basic protein (MBP, provided with the kit) or the O-peptide
(LC Laboratories) were used as PKC substrates. After treatment with
the drugs, as described in the ¢gure legends, the cells were washed
once with ice cold phosphate bu¡ered saline (PBS), and lysed in
20 mM Tris^HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, 10 mM L-glycerophosphate, 0.5 mM phenylmethylsulfonyl
£uoride (PMSF), 2 Wg/ml aprotinin, 2 Wg/ml leupeptin. Insoluble ma-
terial was removed by centrifugation at 13 000Ug for 30 min at 4‡C.
Aliquots of crude extracts were incubated at 30‡C in the presence of
the substrates, 20 mM MOPS, 1 mM NaVO4, 1 mM dithiothreitol,
1 mM CaCl2, 75 mM MgCl2, 500 WM ATP, 200 WCi/ml of [Q-33P]ATP
(s 1000 Ci/mmol, Amersham), 2 WM protein kinase A inhibitor pep-
tide, 20 WM compound R24571, lipid activators. The reactions were
stopped by rapid centrifugation, and the aliquots were spotted on to
P-81 phosphocellulose paper, washed with 75 mM orthophosphoric
acid. Incorporation of 33P was determined by liquid scintillation.
2.4. Northern blot analysis
After treatment of the cells, RNA was puri¢ed. Northern blots were
made with 15 Wg of total RNA in each lane. Blots were hybridized
with a riboprobe synthesized from a pGEM3 vector (Promega, Mad-
ison, WI, USA) containing a 2.3 kb fragment of the AChR K1-subunit
cDNA which overlaps exons 2^6. [32P]UTP (800 Ci/mmol, Amer-
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sham) was used as the label. The same blots were rehybridized with a
muscle creatine kinase (MCK) speci¢c RNA probe, as described pre-
viously [3].
2.5. Quanti¢cation of surface AChRs
Surface AChR levels were measured by 125I labeled K-bungarotoxin
(K-BTG; V200 Ci/mmol, Amersham) binding to myotube cultures as
previously described [2].
2.6. Separation of extracellular [3H]choline and
[3H]phosphorylcholine
To label phosphatidylcholine pools, cells were exposed to 10 WCi of
[methyl-3H]choline chloride for 24 h in culture medium. After label-
ing, cells were washed four times, new minimal essential medium was
added, and cells were incubated for a further 24 h with indicated
drugs. At various times, the incubation medium was removed to tubes
on ice and centrifuged at 200Ug at 4‡C for 10 min. In order to
separate the choline and phosphocholine cell medium was extracted
with tetraphenylboron in heptanone [7]. With this technique,
[3H]choline is extracted into the organic phase while [3H]phos-
phorylcholine (Pcholine) remains in the aqueous phase. Aliquots of
each layer were counted for tritium content.
2.7. Diacylglycerol (DAG) mass determination
Cells were extracted by a modi¢cation of the method of Bligh and
Dyer [8]. Cellular DAG mass was quantitated employing the method
of Preiss et al. [9] using the DAG assay reagent system (Amersham).
2.8. Western blot analysis
After treatment with the drugs, as described in the ¢gure legends,
the cells were washed once with ice cold PBS, and lysed in a bu¡er
containing 20 mM Tris^HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 2 mM sodium orthovanadate, 10 mM L-glycero-
phosphate, 10 mM NaF, 0.5 mM PMSF, 2 Wg/ml aprotinin, 2 Wg/ml
leupeptin. Insoluble material was removed by centrifugation at
13 000Ug for 20 min at 4‡C. The supernatants were subjected to
electrophoresis on SDS^PAGE gels and transferred to nitrocellulose
using a Bio-Rad apparatus. Protein blots were probed overnight at
4‡C with primary antibodies as indicated. Blots were analyzed by
using anti-rabbit IgG conjugated to horseradish peroxidase and visu-
alized by ECL.
3. Results and discussion
In this study we investigated the signal transduction path-
way involved in the repression by electrical activity of AChR
gene expression in chick myotubes. We have previously shown
that okadaic acid blocks the increase of AChR protein and K-
subunit mRNA levels caused by TTX treatment and that this
e¡ect is reversed by staurosporine [10]. Okadaic acid, a spe-
ci¢c inhibitor of protein phosphatases 1 (PP1) and 2A
(PP2A), has been shown to block the di¡erentiation of muscle
cells by abolishing the expression of the genes encoding the
myogenic factors myoD1 and myogenin [11]. Okadaic acid, at
2.5 nM concentration which inhibits AChR protein and K-
subunit mRNA levels in myotubes, selectively inhibits PP2A
[12]. The regulation of Ser/Thr phosphorylation via PP2A has
been implicated in the transcriptional control of cell di¡er-
entiation and proliferation in several cell types [13,14].
Speci¢c inhibitors of conventional PKC, GF109203X,
Go6976 [15], and protein kinase A (PKA), HA1004 [16], failed
to antagonize the repression of AChR K-subunit mRNA and
protein biosynthesis caused by okadaic acid (not shown) or by
spontaneous electrical activity, while the broad spectrum ki-
nase inhibitor staurosporine and TTX completely reversed
these inhibitions (Fig. 1A,B). These data suggest that conven-
tional PKC isoforms or PKA are not involved in the activity
elicited repression of AChR gene expression in myotubes.
This conclusion was further supported by studies with the
general Ser/Thr inhibitor H-7, which inhibits PKC and PKA
with a half maximal concentration of V10 WM [15]. In this
range of concentrations, H-7 did not a¡ect the basal K-sub-
unit mRNA levels in spontaneously contracting myotubes
(not shown).
Ca2 in£ux has been shown to mediate repression by elec-
trical activity [2^4]. We thus tested FK506, a Ca2/calmodulin
dependent Ser/Thr phosphatase (PP2B = calcineurin) inhibitor
[17]. FK506 had no e¡ect on AChR protein and K-subunit
mRNA levels either in the absence or in the presence of TTX
or okadaic acid, excluding a role of calcineurin in the activity
induced repression of AChR genes (not shown).
DAG or another lipid mediator derived from phosphatidyl-
choline (PC) has been implicated in the sustained activation of
Ca2 independent atypical isoforms of PKCs [15,18]. We have
examined whether the PC degradative pathway, or any of the
Fig. 1. E¡ect of 1 WM TTX, 2.5 nM staurosporine (stau), 5 WM
HA1004 (HA), and 1 WM GF109203X (GF) on AChR (A) K-sub-
unit mRNA and (B) surface 125I labeled K-BTG binding sites in my-
otubes. A: Autoradiograms of Northern blot hybridization analysis
of mRNA in chick myotubes treated with indicated drugs. Cells
were treated between days 4 and 6 after plating and total RNA was
extracted. AChR K-subunit and MCK mRNAs were analyzed using
their cRNA probes. The same blot was used for hybridization with
the two probes. The arrows show the position of AChR K-subunit
and MCK mature mRNAs. 3, absence; +, presence of drug.
B: After the indicated treatments between days 4 and 7 surface 125I
labeled K-BTG binding sites were quantitated as described in Sec-
tion 2. The results are expressed as fold increase over untreated val-
ue of cells, and are the means of four separate experiments (means
þ S.D.).
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PKC isoforms, were involved in the repression of AChR genes
by electrical activity. Exogenous application of PC speci¢c
phospholipase C (PC-PLC) and phospholipase D (PC-PLD)
to TTX treated myotubes resulted in a decrease of K-subunit
mRNA levels similar to that obtained by okadaic acid (Fig.
2). PC makes up the largest fraction of total plasma mem-
brane phospholipids and growth factors, cytokines, phorbol
esters and calcium ionophores can cause hydrolysis of PC,
resulting in the sustained elevation of DAG concentration
[19]. The hydrolysis of PC by PLC produces phosphorylcho-
line (Pcholine) and DAG, whereas PLD produces choline and
phosphatidic acid (PA); however, the products of each reac-
tion are interconvertible [20].
We labeled the choline phospholipids of cultured myotubes
by overnight incubation with [3H]choline and assessed the
e¡ect of spontaneous myotube activity on PC metabolism
by treating [3H]choline labeled cells with TTX overnight.
Under control conditions there was a gradual accumulation
of [3H]choline in the cell medium. Inhibition of the electrical
activity of the membrane by TTX reduced this accumulation
by 50%, while [3H]Pcholine accumulation was less a¡ected
(Fig. 3A) suggesting the involvement of PLD. The phorbol
ester PMA also increased the accumulation of [3H]choline in
the cell medium of TTX treated cells, while [3H]Pcholine gen-
eration was not a¡ected (not shown), thus indicating the acti-
vation of PLD by PKC. Phorbol esters and calcium iono-
phores are known to activate PLD in many cell types by
activating conventional PKCs and increasing cytosolic Ca2
[21]. In myotubes, the PKC inhibitor GF109203X was not
able to decrease the accumulation of [3H]choline in the super-
natant of electrically active cells, thus ruling out the direct
involvement of a conventional PKC in PLD stimulation by
electrical activity (not shown).
If electrical activity stimulates the hydrolysis of PC by PLD,
then an increase in PA formation should lead to an increase in
DAG concentration. Six days after plating, DAG levels were
approximately 30% higher in control than in TTX treated
myotubes (Fig. 3B). This suggests that chronic blocking of
the electrical activity of myotubes by TTX inhibits DAG gen-
eration.
We next examined whether PKC activity is regulated by
DAG or by PA produced by PLD activation resulting from
electrical activity. In the in vitro kinase assay, using MBP4ÿ14
as a substrate, the blocking of electrical activity by TTX did
not inhibit the high basal PKC activity. On the other hand,
the PKC inhibitor GF109203X totally inhibited PKC activity,
and the general kinase inhibitor staurosporine partially inhib-
ited it (Fig. 4A). Okadaic acid had no signi¢cant e¡ect on
basal PKC activity. These data suggest that, although a
high level of conventional PKC activity is present in these
myotubes, this activity is not regulated by TTX treatment
under conditions which enhance AChR gene expression. In
contrast, GF109203X, which did not a¡ect AChR gene ex-
Fig. 2. Inhibition of TTX increased AChR K-subunit mRNA levels
by okadaic acid (OA), PC-PLD and PC-PLC. On day 5 after plat-
ing, myotubes were treated with 1 WM TTX, 2.5 nM okadaic acid,
1 U/ml PC-PLD and 1 U/ml PC-PLC as indicated, then further in-
cubated for 2 days. AChR K-subunit and MCK mRNAs were ana-
lyzed as described in Fig. 1A. The arrows show the position of
AChR K-subunit and MCK mature mRNAs. 3, absence; +, pres-
ence of drug.
Fig. 3. Inhibition of (A) release of [3H]choline and (B) formation of
DAG by TTX. A: Between days 5 and 6 after plating myotubes
were labeled with [methyl-3H]choline chloride in the absence (con-
trol) and presence of 1 WM TTX. Cells were washed and and new
medium was added with and without TTX as indicated. After 1 h
medium was collected and measured for release of [3H]choline and
[3H]Pcholine as described in Section 2. B: On day 6 after plating
cells were extracted and cellular DAG mass was quantitated as de-
scribed in Section 2. The results are expressed as percent inhibition
of the value of control cells, and are the means of three separate ex-
periments (means þ S.D.).
FEBS 24404 4-1-01
N. Altiok, J.-P. Changeux/FEBS Letters 487 (2001) 333^338 335
pression, totally abolished conventional PKC activity. We
may note that we have previously shown that conventional
PKCs interfere with the initial step of the stimulatory pathway
triggered by HRG in these myotubes [22].
In examining whether novel or atypical PKC isoforms were
stimulated by electrical activity, we used a synthetic peptide
based on the sequence of the pseudo substrate region of
PKCO, which is a substrate of some of the novel and atypical
PKC isoforms [23]. The basal phosphorylation of O-peptide
was slightly reduced by TTX. GF109203X and staurosporine
also partially though signi¢cantly reduced this activity, while
okadaic acid slightly increased it (Fig. 4B). This is consistent
with the notion that Thr phosphorylation is required for the
activation of all PKCs and that PP2A directly regulates the
activity of atypical PKCs [24]. PKCK also phosphorylates the
O-peptide, and this is possibly a reason why the inhibition by
TTX was so slight. But staurosporine inhibited O-peptide
phosphorylation more strongly than GF109203X, in contrast
to MBP4ÿ14 phosphorylation. These results suggest that the
stimulation of PLD by electrical activity does not lead to the
activation of a conventional PKC isoform, but rather to the
activation of a novel, or atypical, PKC isoform. Our ¢nding
that PKCj is phosphorylated (Fig. 5) and activated (Fig. 4B)
by electrical activity in cultured myotubes is consistent with
previous reports indicating that PLD derived PA activates an
atypical PKC or a novel Ser/Thr kinase [25,26]. However,
despite the observation that okadaic acid and staurosporine
regulate the phosphorylation and the activity of PKCj in a
manner similar to the regulation of AChR gene expression,
TTX treatment did not modify the phosphorylation of PKCj
(Fig. 5).
We have further shown that ATF2 was phosphorylated by
electrical activity, and that this phosphorylation was blocked
by TTX treatment (Fig. 5). ATF2 phosphorylation was also
enhanced by okadaic acid, and this e¡ect was prevented by
staurosporine (Fig. 5). JNK/p38 kinase dependent N-terminal
phosphorylation of ATF2 at Thr-69 and Thr-71 in response
to cellular stress has been shown to be regulated by protein
phosphatases sensitive to okadaic acid [27]. The involvement
of p38 kinase in the repression of AChR genes by electrical
activity was excluded by the fact that the speci¢c inhibitor of
p38 kinase, SB202190, was not able to reverse the inhibitory
e¡ect of okadaic acid or of spontaneous electrical activity on
AChR genes in these myotubes (not shown). Furthermore,
high basal JNK activity in contracting myotubes was blocked
by TTX in in vitro kinase assays using GST-c-jun as a sub-
Fig. 4. E¡ect of 1 WM TTX, 2.5 nM okadaic acid (OA), 1 WM
GF109203X (GF) and 2.5 nM staurosporine (stau) on PKC activ-
ities in myotubes. Between days 4 and 5 after plating the myotubes
were treated with indicated drugs. Then they were lysed and PKC
activity in the crude extracts was determined using (A) MBP4ÿ14
and (B) peptide O. Values obtained are expressed as a percentage of
the activity present in untreated control cells, and are the means of
three separate experiments (means þ S.D.).
Fig. 5. Regulation of threonine phosphorylation of PKCj, ATF2
and Sp1 by 1 WM TTX, 2.5 nM okadaic acid (OA), and 2.5 nM
staurosporine (stau), in myotubes. Myotubes were treated with
drugs as indicated between days 5 and 7. Phosphorylated PKCj
and Sp1 were determined by Western blot analysis using antibodies
speci¢c for phosphothreonine (p-threonine), and phosphorylated
ATF2 (p-ATF2) on separate blots (upper panels). Speci¢cities of the
bands were determined by using respective antibodies against non-
phosphorylated PKCj, Sp1 and ATF2 on stripped membranes (low-
er panels).
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strate (not shown), indicating that JNK most likely phosphor-
ylates ATF2.
PKCj dependent activation of JNKs has been reported in
cardiac myocytes during ischemia [28]. In our studies, phorbol
ester treatment did not stimulate the phosphorylation of
PKCj but caused phosphorylation of ATF2 (not shown),
suggesting that JNK probably lies downstream of PKCj. In-
terestingly, our ¢ndings parallel the observations made in cul-
tured rat ventricular myocytes where the speci¢c isoenzymes
of PKC and JNK were activated either by electrically stimu-
lated contractions or by Ca2 channel agonists [29,30]. JNK is
also activated by intracellular Ca2 in other systems involving
Ca2 stimulated gene expression [31,32]. As shown in these
studies, calcium activation of JNK, with subsequent phos-
phorylation of c-jun, activates gene transcription via interac-
tion between c-jun, the serum response factor (SRF), and the
transactivation domain of Sp1. Together with these studies,
our results suggest the possibility that a similar interaction
may occur at the level of transcription factors interacting
with skeletal muscle AChR gene promoters. Two cis-regula-
tory elements of the AChR K-subunit gene promoter have
been shown to cooperate with the E-boxes in the denervation
response, and one of these regions binds the Sp1 and Sp3 zinc
¢nger transcription factors [33]. In agreement with this obser-
vation, it has been shown that activation of the human car-
diac K-actin promoter in skeletal muscle requires the integrity
of DNA binding sites for the SRF, Sp1 and for the myogenic
factors of the basic helix-loop-helix (bHLH) family [34].
On the basis of these observations, we would like to pro-
pose the hypothesis that: (1) the regulation of muscle speci¢c
genes transcription involves the concerted action of several
transcription factors, including SRF, Sp1 and myogenic
bHLH; and (2) the modi¢cation of one of these factors by
electrical activity stimulated pathway represses AChR genes
transcription.
Consistent with this hypothesis is the observation by Alroy
et al. [35] that a Sp1 containing complex is formed on the N-
box (NDF/heregulin response element) [36] on the promoter
of the AChR O-subunit, and the phosphorylation of Sp1 by
NDF positively regulates the transcription of AChR O-subunit
[35]. Our ¢nding (Fig. 5) that Sp1 phosphorylation is pre-
vented by okadaic acid, which mimics repression by electrical
activity, further supports the proposed hypothesis. Also, Al-
roy et al. [35] have reported that the activation of the AChR
O-subunit by NDF is blocked by okadaic acid, which prevents
Sp1 phosphorylation. These authors have further suggested
that okadaic acid acts on a kinase upstream of Sp1 in the
NDF signalling pathway and that the increased phosphoryla-
tion of that kinase blocks Sp1 phosphorylation.
Our results might be interpreted in a similar framework. An
electrically stimulated kinase may well prevent the phosphor-
ylation of Sp1 in the same manner as okadaic acid, and thus
may repress AChR genes transcription. It is tempting to spec-
ulate that JNK or PKCj may phosphorylate a kinase (or
phosphatase) upstream of Sp1 and, as a consequence, prevent
Sp1 phosphorylation and thus AChR gene transcription. Ac-
cordingly, electrical activity and growth factor action may
share common pathways which, at some stage, would con-
verge on Sp1. It is interesting to note that N-box speci¢c
Ets transcription factors such as GABPK and L are already
known to contribute to the regulation of AChR gene tran-
scription, in addition to the factors mentioned [36]; moreover,
the synergism between the Ets family of transcription factors
and Sp1 is well known in other systems [37].
These studies, however, do not exclude other interactions in
the anticipated complex network of signal transduction path-
ways present in the muscle cell. For example, a direct inter-
action between myogenic factors and JNK may take place.
Indeed, on one of them, Myf5, conserved putative JNK phos-
phorylation sites have been identi¢ed, and the JNK pathway
negatively regulates skeletal muscle myogenesis at their level
[38]. Further work is needed to fully understand the network
of interactions involved in the complex regulation of AChR
gene transcription by electrical activity.
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